HEALTH IN TECH INC. CL.A Aktie

Health In Tech reviewed its financial and operating results for the second quarter on a conference call and filed the transcript as an attachment to a report submitted to the SEC. The SEC filing did not include any additional detailed financial figures; the transcript will be available in the investor relations section for about 90 days. The stock trades on NASDAQ under the symbol HIT at $1.06, but is down roughly 66% year-over-year and 36% year-to-date. Previously, the company reported for Q1/2026 a larger-than-expected loss (EPS -$0.03) on revenue rising to $8.8 million; no analyst updates or M&A news were reported. » More on de.investing.com

Health In Tech reported earnings per share of -$0.03 for Q1 2026, missing the consensus forecast of $0.04. Revenue rose 9% to $8.8 million, but higher operating costs and increased sales and marketing investments led to a net loss of $1.6 million and an adjusted EBITDA of -$1.3 million. The stock fell 1.32% in after-hours trading to $1.50; management continues to stress strategic investments to accelerate future growth and reconfirms a 2026 revenue target of $31.7 million. » More on de.investing.com

Health In Tech sold 5.6 million common shares at $1.25 per share, generating gross proceeds of about $7.0 million. The proceeds are intended for building sales, technology and product development, and working capital. The transaction was led by Craig‑Hallum as placement agent; the company plans to file an SEC registration statement for resale of the shares. Health In Tech reports rising revenues and a current ratio of 3.13, with cash exceeding short‑term liabilities. » More on de.investing.com